The Canadian Pandemic Influenza Plan for the Health Sector
[Previous] [Table of Contents] [Next]
Section Four
RESPONSE
Table of Contents
1.0 Introduction
2.0 Use of Pandemic Phases
3.0 Federal Emergency Response
4.0 The Severe Acute Respiratory Syndrome Experience
5.0 Avian and Animal Influenza
6.0 Key Response Activities by Pandemic Phase
6.1 Interpandemic Period
Canadian Phase 1.0
Canadian Phase 1.1
Canadian Phase 2.0
Canadian Phase 2.1
6.2 Pandemic Alert Period
Canadian Phase 3.0
Canadian Phase 3.1
Canadian Phases 4.0 and 5.0
Canadian Phases 4.1 and 5.1
Canadian Phases 4.2 and 5.2
6.3 Pandemic Period
Canadian Phase 6.0
Canadian Phases 6.1 and 6.2
6.4 Post-Pandemic Period
Response
1.0 Introduction
In this Response Section of the Canadian Pandemic Influenza Plan (the Plan), activities
corresponding to each component (i.e. surveillance, vaccine programs, the
use of antivirals, health services, public health measures and communications)
are organized in a table format by each Canadian pandemic phase. The tables
include the key actions necessary to facilitate a comprehensive and consistent
response to pandemic alerts and an influenza pandemic. However, it is recognized
that additional details and modifications will need to be added as the pandemic
unfolds. For example, it cannot be determined in advance of the appearance
of a novel virus when an effective vaccine might be available; therefore,
all activities listed under “Vaccine Programs” in the tables may occur at
different phases than the ones that are currently listed (in the tables).
2.0 Use of Pandemic Phases
The pandemic phases declared by the World Health Organization (WHO) are
based on the evaluation of pandemic risk situations, with the declared
phase representing the highest global risk. Therefore if there is concurrent
circulation of two or more novel influenza viruses, the phase will correspond
to the situation presenting the highest risk of pandemic. In April 2005,
WHO published new terminology for pandemic phases, which replaced the
terminology published in 1999. The new terminology includes six phases
spanning three pandemic periods: Interpandemic Period, Pandemic Alert
Period and the Pandemic Period. A Post-Pandemic Period has also been identified
but it is not linked to a numerical phase.
To succinctly summarize the global situation and the situation in Canada,
the Pandemic Influenza Committee (PIC) developed Canadian pandemic phase
terminology that combines the WHO phase and an indicator of the highest
level of novel influenza activity in Canada. The Canadian pandemic phases
are described in the Background Section of the Plan. In general, the nomenclature
is the WHO phase followed by a decimal point and then 0, 1 or 2 to indicate
absence of cases, single (unlinked) cases, or localized or widespread
activity in Canada (e.g. 3.1). This Response Section has been updated
since it was first published in February 2004 to include this terminology.
For responders at the time of a pandemic, the focus will be on more localized “triggers” that
may or may not correspond to the Canadian pandemic phase because the phase is based on
the highest level of novel influenza activity observed in Canada. It is expected that differences
in influenza activity within Canada will be described on the basis of surveillance data that is
reported similarly to that during the annual influenza season. Planners at all levels in the health
and emergency service sectors, from municipal to federal, are encouraged to think about the
“phase” under which their specific jurisdictions would fall based on influenza activity within the
jurisdictions. This is so they can operationalize an appropriate response for the jurisdiction,
recognizing that their plans will also be affected by the epidemiology of the pandemic
nationally and globally.
Other unknown factors (e.g. age distribution, severity of the illness caused by the pandemic
strain, efficiency of transmission from human to human) will also affect the response
measures. The Plan assumes that progression to a pandemic will occur if novel influenza
activity occurring during the Pandemic Alert Period is not halted. Therefore the response to
novel virus activity during the Pandemic Alert Period may need to be significantly modified
from what is outlined in this Plan if the epidemiology (e.g. of a domestic AI outbreak) does not
suggest the need for aggressive measures.
3.0 Federal Emergency Response
Planning at the federal level has resulted in the development of a generic emergency
management structure. This structure, which indicates roles and responsibilities of specific
groups in response to an emergency, is included in Annex L, Federal Emergency
Preparedness and Response System. The specific composition, roles and responsibilities of
the Advance Planning Group still need to be determined; however, members that can provide
technical advice specific to pandemic influenza will be essential.
Also included in Annex L is a flow diagram that aligns response activities with the phases. This
tool provides a visual overview of the response from a federal perspective.
The Canadian Pandemic Influenza Plan is a disease-specific plan. It is an example of a specific,
technical emergency plan that has been developed as part of much larger initiative to create
plans to deal with all types of national emergencies. By creating a set of plans that are
increasingly specific, i.e. range from generic emergency response issues to more specific
threats (e.g. infectious diseases) and finally to detailed disease-specific threats, it is
anticipated that a set of “nested” or linked documents will be available; these nested
documents will be comprehensive and flexible enough to cover off any type of national
emergency.
4.0 The Severe Acute Respiratory Syndrome Experience
Prior to March 2003, when the severe acute respiratory syndrome (SARS) arrived in Canada,
the vast majority of health care professionals and certainly the general public had limited
personal experience with large outbreaks of serious respiratory infections. The SARS outbreak
caused an exponential increase in the knowledge of and experience with this type of health
threat. Awareness of SARS, the severity of the illness, method of spread and the
implementation of control measures penetrated Canadian society from coast to coast
regardless of the actual case count in each province or territory.
Those involved in disease surveillance and pandemic planning saw SARS as a type of
"dress-rehearsal" for pandemic influenza. They recognized that many of the response issues
would be the same but on a much larger scale. Although the costs due to SARS were high in
terms of morbidity and mortality and economic losses, the costs of pandemic influenza have
the potential to be much greater. The response to pandemic influenza also would need to be
sustained for a longer period of time and would likely include a mass immunization effort on
top of the demands of acute care for patients.
The SARS experience reinforced the need for preparedness activities as cited in the
Preparedness Section of the Plan. In particular, the need for resources and surge capacity
within the health system to deal with public health emergencies is highlighted. Advanced
preparation and removal of potential barriers in communication systems, data management
technology, and the acquisition and mobilization of supplemental health care workers and
settings are just a few of the other needs identified in the Plan and validated by the SARS
experience.
It is with this experience behind us that those involved in drafting this Plan have identified the
key action items listed in this Response Section.
5.0 Avian and Animal Influenza
Outbreaks caused by novel influenza viruses in avian or animal populations present
opportunities for transmission to humans. Sporadic human infection with a number of avian
(e.g. H5, H7, H9) and swine (e.g. H1N1) influenza subtypes have been documented. In
addition, there may be opportunities for reassortment between animal and human influenza
viruses when they simultaneously infect the same swine or human host. Such reassortment
events may result in the development of a new influenza virus subtype with pandemic
potential.
Since 2003, an unprecedented number of avian outbreaks of influenza have been detected
worldwide. Human cases, ranging in severity from conjunctivitis to fatal cases, have resulted
from these various outbreaks. The WHO global phases now include the occurrence of avian
and animal influenza outbreaks and the role of these outbreaks as potential precursors to a
pandemic.
As a result of the avian outbreak of H7N3 in British Columbia in 2004, a guideline
document was developed by PHAC to provide recommendations for public health
authorities and other stakeholders involved in the management of actual
and potential human health issues related to domestic avian influenza
outbreaks. This document has recently been updated and expanded to include
guidance on the management of all AI events with potential human health
implications (see Human Health Issues Related to Avian Influenza in
Canada, on the PHAC website). Because the actions in the guideline
document pertain to the new Canadian Phases 1.1, 2.1 and 3.1, the human
health issues document is referenced in the tables in section 6 below.
Although the control of animal influenza outbreaks is a key part of preventing
the emergence of a human influenza pandemic—and there are critical animal
and human health linkages—the responses to the actual animal outbreaks
are best addressed in animal health guidelines and plans. The Canadian
Food Inspection Agency (CFIA) is the lead agency for AI outbreak response
and animal health and food safety issues.
6.0 Key Response Actions by Pandemic Phase
The key response actions listed in the following tables are organized by the component of the
response to which they relate (Component) and by the phase during which each action should
take place (Phase). High-level activities for emergency management and coordination have
also been added to the tables. It is assumed that each jurisdiction will refer to the phase that is
consistent with their respective levels of novel influenza activity. For example, if the southern
part of one province is experiencing localized pandemic activity, the Canadian Phase would be
6.2 (the Canadian Phase always reflects the highest level of activity in the country) and the
geographic areas or region with the activity would follow the actions under Phase 6.2. However if no other pandemic activity was occurring in Canada at that time, then the areas
with no known cases would take the actions consistent with Phase 6.0 until they started to
experience pandemic activity.
As previously discussed, flexibility in the response is needed because the availability of
resources (e.g. vaccine, antiviral drugs) may require deviation from the proposed sequence of
response actions. It is expected that many of the response actions under each phase will need
to occur simultaneously. The action items have not been prioritized within each phase. More
detailed actions are provided in many of the technical annexes.
Response actions and messages are organized by pandemic period rather than by Canadian
phase in Annex K, Communications; therefore, readers are referred to this annex in each of
the phase-specific tables below.
The tables also include Response Level designations (see legend below) that
are provided for guidance only. It is likely that many response actions,
especially those for which national consistency is desirable, will be
led by PIC or collaborative federal, provincial, territorial processes.
Other non-governmental responders (e.g. Salvation Army, Red Cross) will
be likely involved in the response but have not been specifically identified
in the Plan because it is anticipated that their respective roles and
activities would be developed in conjunction with public health authorities
at the P/T, regional and local level.
Legend for the Canadian Pandemic Phase Tables
Acronyms for organizations
CATMAT = Committee to Advise on Tropical Medicine and Travel
CEPR = Centre for Emergency Preparedness and Response
CIHR = Canadian Institutes for Health Research
CPHLN = Canadian Public Health Laboratory Network
HPFB = Health Products and Food Branch
NACI = National Advisory Committee on Immunization
NML = National Microbiology Laboratory
PHAC = Public Health Agency of Canada
PWGSC = Public Works and Government Services Canada
Abbreviations for response levels
F = Federal
L = Local
P/T = Province/Territory
Note: The term "animal" in the tables below is intended
to cover both avian
and animal species. |
6.1 Interpandemic Period
Canadian
Phase 1.0 |
No new virus subtypes in humans, animals outside Canada may be infected with a new subtype that is considered low risk
for humans |
Component |
Focus |
Actions |
Response Level |
Surveillance |
Pandemic
Preparedness activities |
- As per Preparedness Section
- Ensure links to veterinary
counterparts are in place as part
of general pandemic
preparedness
- Routine human influenza
surveillance
|
F,P/T, L |
Information sharing |
- Disseminate available surveillance
information from countries
experiencing animal cases and/or
outbreaks to public health
stakeholders
|
F (Lead: PHAC) |
- Provide updates on ongoing risk
assessment for pandemic influenza
potential
|
F (Lead: PHAC) |
Public Health
Measures |
Public education |
- If animal outbreaks are occurring:
- Provide general travel health
information pertaining to safe
food handling, respiratory
etiquette
|
F (Lead : PHAC) |
All other
components |
Pandemic
Preparedness activities |
|
|
Emergency Management and
Coordination |
|
- Develop/maintain response plans
|
F,P/T, L |
- Explore need to stockpile (e.g.
syringes, other medical supplies)
|
F,P/T, L |
- Identify how essential services will be
maintained during a pandemic
|
F,P/T, L |
|
F,P/T, L |
- Train staff that may be re-assigned
during a pandemic
|
F,P/T, L |
Canadian Phase 1.1 |
No new virus subtypes in humans, animal(s) inside Canada infected with a new subtype that is considered low risk for
humans |
Component |
Focus |
Actions |
Response Level |
Surveillance, Vaccine Programs, Antivirals, Health Services,
Public Health Measures, Communications |
Veterinary Outbreak Control |
- As per Human Health Issues Related to Avian Influenza in
Canada document; Rapid sharing of information among animal
and human health professionals
|
F,P/T, L |
Prevention of Human Infection |
- Provide updates on ongoing risk assessment for pandemic influenza
potential and make recommendations for increased vigilance for
surveillance and public health action
|
F,P/T, L |
Emergency Management and Coordination |
- Continue as per Phase 1.0 actions and;
|
|
- Ensure that response network is ready to respond
|
F,P/T, L |
- Provide technical information liaison
|
F,P/T, L |
- Report situation to PSEPC (daily report)
|
F (Lead : PHAC) |
- Share PHAC/HC info with regional officers
|
F (Lead : PHAC) |
- Facilitate sharing of information between animal and human health
authorities
|
F (Lead : PHAC) |
Canadian Phase 2.0 |
No new virus subtypes in humans, animals outside Canada infected with a new subtype that has a substantial risk for
humans |
Component |
Focus |
Actions |
Response Level |
Surveillance, Vaccine Programs, Antivirals, Health Services,
Public Health Measures, Communications |
Pandemic preparedness, Information sharing, Public education |
- As per Phase 1.0 with messages reflecting the increased risk
to human health
|
F,P/T, L |
- Design and seek agreement on a common strategy for the communication
of epidemiological data (nationally and with WHO internationally)
|
F,P/T, L |
Emergency Management and
Coordination |
- As per Phase 1.1 with increased
communications/liaison with other
government departments
|
F,P/T, L |
Canadian Phase 2.1 |
No new virus subtypes in humans, animals inside Canada infected with a new subtype that has a substantial risk for
humans |
Component |
Focus |
Actions |
Response Level |
Surveillance, Vaccine Programs, Antivirals, Health Services,
Public Health Measures, Communications |
Veterinary Outbreak Control |
- As per Human Health Issues Related to Avian Influenza in
Canada document
|
F,P/T, L |
Prevention of Human Infection |
- All measures would reflect the increased risk associated with
this novel virus
|
F,P/T, L |
Emergency Management and Coordination |
|
F,P/T, L |
6.2 Pandemic Alert Period
Canadian Phase 3.0 |
Human infection(s) with a new virus subtype
occurring outside Canada - no or at most rare instances of
human to human transmission. |
Component |
Focus |
Actions |
Response Level |
Surveillance |
Establish and/or heighten existing surveillance systems |
- Verify epidemiological data and current risk assessment from
official sources (WHO, Ministries of Health)
- Review and confirm that all inter-pandemic surveillance activities
(via FluWatch) are operating optimally
|
F (Lead: PHAC) |
Information sharing |
- Convey current international risk assessment in Canadian context
- Provide information and national recommendations to F/P/T stakeholders
|
F, P/T, L (Lead: PHAC) |
Vaccine Programs |
Mitigation of potential complications of influenza through
use of current vaccine resources |
- Promote use of annual influenza vaccine
- Promote pneumococcal vaccination to "high-risk" and age-specific
target groups to reduce the incidence and severity of secondary
bacterial pneumonia
|
P/T, L |
- Collaborate on international vaccine development initiatives,
including the development and testing of prototype vaccine strains
as needed.
|
F (Lead: PHAC) |
- Review pandemic vaccine infrastructure readiness with domestic
manufacturer
|
F (Lead: PHAC) |
Antivirals |
Review of preparedness status and updating of strategy |
- Assess and/or re-assess availability of antiviral medications
|
F,P/T,L |
- Review recommended priority groups and plans for antiviral use
based on available epidemiological data
- Consider adequacy of stockpiled quantities in light of estimated
sizes of the respective priority groups in your jurisdiction
|
F,P/T
F,P/T |
- Review and modify if necessary, contingency plans for storage,
distribution and administration of antiviral drugs through public
health and other providers to nationally defined priority groups
|
F,P/T,L |
Communication and education |
- Communicate antivirals strategy as part of pandemic educational
materials (including which priority groups will likely be covered,
current supply and any shortfalls)
|
F,P/T,L |
- Ensure staff are trained and infrastructure is in place to track
who is receiving the drugs for the purpose of treatment and prophylaxis
|
F,P/T,L |
Health Services |
Evaluation of laboratory capacity
Information gathering |
- Ensuring at least one laboratory within the P/T has the capability
to isolate and subtype influenza virus, and if not establish anticipatory
"back-up" process
|
P/T (Lead: CPHLN) |
- Ensure that estimates of health care personnel capacity are
current (i.e., estimated number of health care workers (HCWs)
by type (physician, nurses, respiratory therapists, radiology
technicians, etc), and by work setting (hospital, community, LTCF,
para
- Identify if possible HCWs by type of work that they usually
do
|
F,P/T,L |
Public Health Measures |
Information preparation |
- As per Annex M (Public Health Measures)
- Review and update educational materials on all aspects of influenza
for health care professionals, travellers, other special audiences
and the general public
|
F,P/T,L |
Communications |
|
|
|
Emergency Management and Coordination |
- Provide case count to PSEPC
|
F (Lead: PHAC) |
- Notify P/T's emergency service
managers (ESS+CHEMD)
|
F (Lead: PHAC) |
- Coordinate international
consultations (WHO/CDC)
|
F (Lead: PHAC) |
|
F (Lead: PHAC) |
|
F (Lead: PHAC) |
Canadian Phase 3.1 |
Sporadic human infection(s) with a new virus
subtype occurring inside Canada - no or at most rare instances
of human to human transmission. |
Component |
Focus |
Actions |
Response Level |
Surveillance |
Monitoring of evolving situation |
- Investigation of sporadic cases, including collection of detailed
epidemiologic data, contact tracing, and public health monitoring
- Ensure that enhanced surveillance is in place across Canada
for rapid detection of potential spread
|
F (Lead : PHAC),
P/T |
Dissemination of data |
- Review/Revise standard reports for dissemination of epidemiological
data within Canada
- Establish and convey current risk assessment to national and
international surveillance partners
- Dissemination of epidemiological data, as needed
- If occurring in conjunction with an animal outbreak in Canada
– refer to Human Health Issues Related to Avian Influenza
in Canada document for more details
|
F (Lead: PHAC)
F, P/T |
Vaccine Programs |
Reduce potential for genetic re-assortment |
- Immunize close contacts of cases with annual influenza vaccine
if available as per Annex M (Public Health Measures)
|
F, P/T, L |
Inventory and resource assessment |
- Conduct initial availability assessment of supplies (e.g. syringes,
adrenalin, sharps disposal units), equipment and locations potentially
required for a vaccine-based response (i.e., mass clinics)
|
Preparation (Legal, Educational etc.) |
- Develop list of currently qualified vaccinators and sources
of potential vaccinators
|
F, P/T, L |
- Review educational materials re. Administration of vaccines
and adapt/update as needed
|
F, P/T, L |
- Ensure that any legal issues that may impede rollout of a mass
immunization program are addressed
|
P/T, L |
- Ensure domestic vaccine manufactures are alerted and participating
in international efforts
|
F (Lead: PHAC) |
Antivirals |
Antiviral strategy |
- Use neuraminidase inhibitors for treatment of cases as per Annex
M (Public Health Measures)
- Perform an inventory assessment (drugs, formulations, and expiry
dates)
- Test stockpiled antivirals for potency if necessary (i.e., if
past expiry date)
|
F,P/T (Lead: PHAC) |
Health Services |
Rapid case confirmation |
- Laboratory testing as per Annex C (Laboratory Procedures)
|
P/T (Lead: CPHLN) |
Guideline review and/or revision |
- Review protocols and guidelines for prioritization of laboratory
services during times of high service demand and staff and supply
shortages
|
P/T (Lead: CPHLN) |
Preparation (Legal, Educational etc.) |
- Ensure that any legal and insurance issues that may impede recruitment
and use of active and retired health care workers and volunteers
have been addressed with P/T licensing bodies
|
P/T |
- Prepare and/or update communications defining the extent of
care that health care workers and volunteers can perform according
to P/T laws and union agreements
|
P/T |
Case and Contact management |
- Manage cases and contacts as per recommendations in Annex M
(Public Health Measures)
- Isolation of cases
- Surveillance of contacts
|
F, P/T, L |
Public Health Measures |
Resource assessment and preparation |
- Review staffing requirements for implementation of a pandemic
response including mass immunization clinics, control measures,
and public education
|
|
- Consider delaying introduction of public health programs that
may not be adequately resourced if situation evolves into a pandemic
or other alternatives such as contracting out
|
P/T, L |
- Preparation of educational material for public
|
F, P/T, L |
Communications |
|
|
|
Emergency Management and Coordination |
|
|
- Report to International Health Regulations as required
|
F (Lead : PHAC) |
- Assess risk and disseminate
information to and with
stakeholders
|
F,P/T, L |
|
F (Lead : PHAC) |
- Review medical personnel availability
|
F,P/T, L |
- Review federal legislative
authorities
|
F,P/T, L |
- Aquire (when available) and disseminate any laboratory testing
materials (i.e., reagents)
|
F (Lead:
NML/CPHLN) |
Canadian Phases 4.0 and 5.0 |
Clusters with limited human-to-human transmission
occurring outside of Canada, spread is localized, no cases
in Canada |
Component |
Focus |
Actions |
Response Level |
Surveillance |
Establish and/or Heighten enhanced surveillance systems |
- Verify epidemiological data and current risk assessment from
official sources
|
F (Lead : PHAC) |
- Enhance current surveillance activities based on circumstances
|
F, P/T, L |
- Review and/or revise case definitions, minimum data sets, and
data collection forms
|
F, P/T (Lead: PIC) |
Border issues |
- Implement border-based surveillance (depending on origin of
cases) coordinated by CEPR, as per Annex M (Public Health Measures)
- Include notifications to ill and well travellers
|
F, P/T (Lead: PHAC) |
Plan for streamlined data collection |
- Initiate ramped up surveillance activities to detect and monitor
increased morbidity and mortality
|
P/T, L |
Dissemination of data |
- Review and/or revise standard reports for dissemination of epidemiological
data within Canada
|
F, P/T, L |
Vaccine Programs |
Planning for vaccine distribution |
- Ongoing involvement in vaccine development initiatives
|
F (Lead: PHAC with vaccine manufacturers) |
Mass campaign infrastructure |
- Review and modify if necessary, contingency plans for storage,
distribution and administration of influenza vaccine through public
health and other providers to nationally defined high-priority
target groups (See Annex J for use of non-traditional sites and
workers)
|
F,P/T (Lead: PIC) |
- Ensure staff are trained and infrastructure is in place to record
immunizations, including requirements for a two-dose immunization
program (i.e. re-call and record-keeping procedures)
|
P/T, L |
- Review estimates of the number of people within the P/T who
fall within each of the priority groups for vaccination (i.e.,
high risk groups, health care workers, responders, specific age
groups) and access strategies
|
F, P/T, L |
- Ongoing promotion of current annual influenza vaccine for NACI
recommended groups and for travellers (as per CATMAT recommendations)
|
F, P/T (Lead: PIC/NACI) |
Antivirals |
Supply of antiviral drugs |
- Perform an inventory assesment of available supplies
|
F,P/T (Lead: PHAC) |
Planning for antiviral drug distribution and tracking |
- Review recommended priority groups and plans for antiviral use
based on available epidemiological data
|
F,P/T (Lead: PIC) |
- Review and modify if necessary, contingency plans for storage,
distribution and administration of antiviral drugs through public
health and other providers to nationally defined high-priority
target groups
|
F,P/T,L |
- Review estimates of the number of people within the P/T who
fall within each of the priority groups for receipt of antiviral
drugs (i.e., high risk groups, health care workers, responders,
specific age groups) and access strategies
|
F,P/T,L |
- Ensure staff are trained and infrastructure is in place to track
who is receiving the drugs for the purpose of treatment and prophylaxis
|
P/T,L |
Health Services |
Prepare for management of suspect cases detected through
enhanced surveillance |
- Implement/Review infection control precautions for case management
|
F, P/T, L (Lead: PHAC) |
- Review national recommendations for clinical management of cases
and modify if necessary
|
F, P/T (Lead: PIC) |
- Anticipate and plan to mobilize human and financial resources
|
F, P/T, L |
Preparation for increased demand on acute care sites |
- Review and update local and P/T data on the number & type of
health care facilities, and capacity: hospital beds, ICU beds,
swing beds, LTC beds with enhanced level of care, emergency department,
ventilatory capacity, oxygen supply, antibiotic supply
|
P/T, L |
- Conduct availability assessment of medications, supplies and
equipment potentially needed for the response
|
P/T, L |
- Review, modify, and distribute P/T guidelines (or national guidelines)
for prioritizing health care needs and service delivery, accessing
resources and implementing infection control measures during a
pandemic
|
F, P/T, L |
- Disseminate information on medical supply stockpiles and potential
need for, and sources of, additional supplies
|
F, P/T (Lead: PHAC) |
- Review, modify, and distribute detailed regional and facility-level
plans for providing health services during a pandemic, including
the type of care to be delivered at non-traditional health care
settings and the triage across sites; human resource, mate
|
P/T, L |
- Disseminate strategy for collecting and monitoring data on health
care service use and demands
|
P/T, L |
Public Health Measures |
Preparation of educational materials and public health
resources |
- Review national recommendations as per Annex M (Public Health
Measures) for public health management of cases and other control
measures and modify if necessary
|
F, P/T (Lead: PIC) |
- Ensure adequate resources are available to implement recommended
public health measures including isolation of cases
|
P/T, L |
- Prepare and revise (if necessary) educational and guidance materials
for public health partners (specifically provincial/territorial
and local health departments who will be on the front lines with
respect to prevention and control measures), the general
|
F, P/T, L |
Communications |
|
|
|
Emergency Management and Coordination |
- For Phase 4.0 -actions as per Phase
3.1 and;
|
|
- Prepare to respond to GOARN request for participation
|
F (Lead: PHAC) |
- Anticipate and plan to mobilize human and financial resources
|
F,P/T, L |
- Disseminate information on medical supply stockpiles and potential
need for sources of additional supplies
|
F,P/T, L |
- Alert voluntary organisations
|
F,P/T, L |
- For Phase 5.0 -actions as per Phase
4.2
|
F,P/T, L |
Canadian Phases 4.1 and 5.1 |
Sporadic infection(s) with virus that has demonstrated
limited human-to-human transmission detected in Canada. No clusters
identified in Canada but clusters have occurred outside of Canada |
Component |
Focus |
Actions |
Response Level |
Surveillance |
Prompt identification of any secondary cases Collect,compile
and distribute epidemiological data for cases reported in Canada |
- Collection and dissemination of epidemiological and clinical
data for cases occurring in Canada
- Review and if necessary, revise case definitions, minimum data
sets, and data collection forms
|
F,P/T, L |
- Review protocols for special studies and prepare dedicated teams
as necessary to ensure prompt activation of the studies when appropriate
|
F. P/T, L (Lead: CIHR or other NGO) |
Vaccine Programs |
Vaccine development |
- Ongoing involvement in vaccine development, testing and production
initiatives
|
F (Lead: PHAC HPFB, manufacturers) |
Preparation for mass immunization clinics |
- Review and modify if necessary, plans for vaccine security (i.e.,
during, transport, storage and clinic administration)
|
P/T, L |
Implementation of targeted immunization clinics |
- If a potentially effective vaccine is available:
|
|
- Follow national recommendations for use of the available vaccine
|
P/T, L |
- Implement streamlined VAAE surveillance, in collaboration
with PHAC
|
F, P/T, L (Lead: PHAC) |
- Arrange for direct shipping of vaccine to health districts
|
F (Lead: PWGSC) |
Antivirals |
Localized use of antivirals (treatment and prophylaxis
of contacts) for containment purposes |
- Treat cases and provide prophylaxis for contacts of cases, based
on local epidemiology and available supplies as per Annex M (Public
Health Measures)
|
P/T, L |
- Ensure prompt mobilization of antivirals supplies allocated
for early containment
|
F, P/T (Lead: PHAC) |
- Ensure that stakeholders are aware of how to report adverse
drug reactions if antivirals are being used
|
F, P/T, L |
Health Services |
Use of optimal infection control practices to prevent
spread |
|
|
- Evaluate infection control and occupational health recommendations
and practices and revise as necessary
|
F, P/T (Lead: PHAC) |
Public Health Measures |
Resource and risk assessment |
- Ensure adequate resources are available to implement recommended
public health measures including isolation of cases
|
P/T,L |
- Establish current level of risk to guide public health actions
(e.g. transmission characteristics associated with secondary cases)
|
P/T,L |
Case and Contact management |
- Manage cases and contacts as per recommendations in Annex M
(Public Health Measures)
- Isolate cases
- Quarantine or activity restriction of contacts
- Update educational material (with Communications staff)
|
P/T,L |
Advance planning |
- Review staffing requirements for implementation of a pandemic
response including mass immunization clinics, control measures,
and public education
|
P/T,L |
- Consider delaying introduction of public health programs that
may not be adequately resourced if situation evolves into a pandemic
or other alternatives such as contracting out
|
P/T,L |
Communications |
|
|
|
Emergency Management and Coordination |
- For Phase 4.1 -actions as per Phase
4.0
|
F,P/T,L |
- For Phase 5.1 -as per Phase 4.2 and;
- Prepare dedicated team as
necessary
|
F,P/T,L |
Canadian Phases 4.2 and 5.2 |
Localized cluster(s) with limited human-to-human
transmission occurring in Canada but spread is localized, suggesting
that the virus is not yet well adapted to humans or fully transmissible |
Component |
Focus |
Actions |
Response Level |
Surveillance |
Timely collection, compilation and dissemination of
epidemiological and clinical data |
- Refer to actions from phase 4.1, 5.1
|
F (Lead: PIC) |
- Revise case definitions based on observed clinical presentation
of cases
|
F, P/T, L |
- Implement any special studies identified for these phases
|
F, P/T, L (Lead: CIHR or other NGOs) |
Vaccine Programs |
Vaccine development |
- Ongoing involvement in vaccine development, testing, and production
initiatives
|
F (Lead: PHAC HPFB, manufacturers) |
Preparation for mass immunization clinics |
- Review recommended priority groups for immunization based on
available epidemiological data
|
F,P/T (Lead: PIC) |
- Review and modify if necessary, plans for vaccine security (i.e.,
during, transport, storage and clinic administration)
|
P/T, L |
Implementation of targeted immunization clinics |
- As per Phases 4.1 and 5.1, if a potentially effective vaccine
is available
|
|
- Follow national recommendations for use of the available vaccine
|
P/T, L |
- Implement streamlined VAAE surveillance, in collaboration
with PHAC
|
F, P/T, L (Lead: PHAC) |
- Arrange for direct shipping of vaccine to health districts
|
F (Lead: PWGSC) |
Antivirals |
Localized use of antivirals (treatment and prophylaxis
of contacts) for containment purposes |
- As per Phases 4.1 and 5.1
|
|
- Treat cases and provide prophylaxis for contacts of cases,
based on local epidemiology and available supplies as per Annex
M (Public Health Measures)
|
P/T,L |
- Ensure prompt mobilization of antivirals supplies allocated
for early containment
|
F, P/T (Lead: PHAC) |
- Ensure that stakeholders are aware of how to report adverse
drug reactions if antivirals are being used
|
P/T, L |
Health Services |
Use of optimal infection control practices Management
of increased demand on health care system |
- Evaluate infection control and occupational health recommendations
and practices and revise as necessary
|
F, P/T (Lead: PHAC) |
- Ensure protocols and guidelines for prioritization of laboratory
services during times of high service demand and staff and supply
shortages have been distributed
|
P/T, L |
- Review and implement mechanisms for coordinating patient transport
and tracking/managing beds (e.g. central bed registries, call
centre and centralized ambulance dispatch)
|
P/T, L |
Public Health Measures |
Outbreak control and containment |
- Manage cases and contacts as per recommendations in Annex M (Public Health Measures)
- Isolate cases
- Quarantine or activity restriction of contacts
|
F, P/T, L |
- Evaluate interventions and revise recommendations as necessary
|
F, P/T |
- Integrate national recommendations for isolation into practice
at the local level
|
P/T, L |
- Implement use of mandatory isolation orders if necessary
|
F, P/T |
- Review and, if necessary, update and disseminate national recommendations
regarding containment strategies (i.e., cancellation of public
gatherings, school closures) as per Annex M (Public Health Measures)
|
P/T, L |
- Monitor and track compliance with containment recommendations
|
L |
- Develop or update educational materials for the public and health
care providers as the situation evolves
|
F, P/T, L |
Communications |
|
|
|
Emergency Management and Coordination |
- For Phase 4.2 -actions as per Phase 4.0
|
|
- Consider sending a Liaison Officer to CDC (and vice versa)
|
F (Lead : PHAC) |
- Implement use of mandatory isolation orders if necessary in
federal jurisdictions
|
F (Lead: PHAC) |
- For Phase 5.2 -actions as per Phase 5.1
|
|
6.3 Pandemic Period
Canadian Phase 6.0 |
Outside Canada, increased and sustained transmission
in the general population has been observed (i.e., pandemic activity).
No cases have been identified in Canada |
Component |
Focus |
Actions |
Response Level |
Surveillance |
Timely collection, compilation and dissemination of
epidemiological and clinical data |
- Verify international epidemiological data and current risk assessment
from official sources
|
F (Lead: PHAC) |
- Revise case definitions based on international assessment of
observed clinical presentation of cases
|
F (Lead: PHAC) |
- Distribute data collection forms and database transmission instructions
and protocols if not done previously
|
F, P/T (Lead: PHAC) |
- Follow any new recommendations regarding a switch-over to aggregate
reporting of data
|
F, P/T (Lead: PHAC) |
- Review protocols for special studies and prepare dedicated teams
as necessary to ensure prompt activation of the studies when appropriate
|
F. P/T, L (Lead: CIHR or other NGO) |
Vaccine Programs |
Vaccine development |
- Ongoing involvement in vaccine development, testing and production
initiatives
|
F (Lead: PHAC HPFB, manufacturers) |
Preparation/Implement ation of mass immunization clinics |
- Review and if necessary revise recommended priority groups for
immunization based on available epidemiological data
|
F, P/T (Lead: PIC) |
- Review and if necessary revise recommended priority groups for
immunization based on available epidemiological data
|
P/T, L |
- Modify or refine of nationally defined priority target groups
depending on local circumstances
|
P/T, L |
- Modify or refine other aspect of the federal guidelines, as
needed for P/T and local application
|
P/T, L |
- Review and modify if necessary, plans for vaccine security (i.e.,
during, transport, storage and clinic administration)
|
|
- When vaccine is available
|
|
- National coordination on vaccine purchase
|
F,P/T (Lead: PWGSC) |
- Activate immunization clinic capability
|
P/T,L |
- Implement streamlined VAAE surveillance, in collaboration
with PHAC
|
F, P/T, L (Lead: PHAC) |
- Arrange for direct shipping of vaccine to health districts
|
F (Lead: PWGSC) |
- Communicate with bordering jurisdictions (other P/Ts and the
U.S.) to facilitate awareness of the vaccine distribution plan
and coordination and collaboration on efforts as much as possible
|
F, P/T, L |
Antivirals |
Strategic and controlled use of antivirals |
- Review and if necessary revise national recommendations on antiviral
use based on available epidemiological data
|
F, P/T (Lead: PIC) |
Health Services |
Use of optimal infection control practices
Preparation for increased demand on health care system |
- Evaluate infection control and occupational health recommendations
and practices and revise as necessary
|
F, P/T (Lead: PHAC) |
- Review protocols and guidelines for prioritization of laboratory
services during times of high service demand and staff and supply
shortages
|
P/T, L |
- Review mechanisms for coordinating patient transport and tracking/managing
beds e.g. central bed registries, call centre and centralized
ambulance dispatch
|
P/T, L |
- Contact and prepare sources of additional HCWs and volunteers
i.e., Emergency Measures Organizations and NGOs (Red Cross, St.
John ambulance)
|
F, P/T, L (Lead: PHAC) |
- Acquire extra supplies needed to provide medical care in non-traditional
sites
|
P/T, L |
Public Health Measures |
Preparation of implementation of public health response |
- As per Phases 4.0 and 5.0
|
|
- Review national recommendations as per Annex M (Public Health
Measures) for public health management of cases and other control
measures and modify if necessary
|
F, P/T, L |
- Ensure adequate resources are available to implement recommended
public health measures including isolation of cases
|
P/T, L |
- Prepare and if necessary revise educational and guidance materials
for public health partners (specifically, P/T and local health
departments who will be on the front lines with respect to prevention
and control measures), the general public; Some documents for
the public should emphasize infection control in homes, schools,
places of work
|
F, P/T, L |
Communications |
|
|
|
Emergency Management and Coordination |
- As per Phase 5.1
- Ensure NESS resources are ready to be deployed
- Contact and prepare sources of additional HCWs and volunteers
(NGO's)
|
|
Canadian Phases 6.1 and 6.2 |
Pandemic virus detected in Canada (Phase 6.1
– single case(s) occurring, Phase 6.2 – localized or widespread activity
occurring) |
Component |
Focus |
Actions |
Response Level |
Surveillance |
Timely collection, compilation and dissemination of
epidemiological and clinical data |
- 6.1: Confirm that clinical spectrum of disease (based on feedback
from local level experts), is consistent with what is being observed
internationally (revise case definitions if necessary)
|
F, P/T, L |
- 6.2: Scale back to streamlined surveillance
|
F, P/T (Lead: PHAC) |
- 6.2: Implement any special studies identified for these phases
|
F, P/T, L (Lead: possibly PHAC, PIC and/or CIHR) |
Monitoring the progress of pandemic |
- 6.2: When indicators suggest activity appears to be decreasing
(i.e., end of a pandemic wave)
|
|
- Determine ongoing surveillance needs for both documentation
of end of first wave and detection of any new cases or outbreaks
|
F, P/T, L (Lead: PIC) |
Vaccine Programs |
Vaccine development |
- As per Phase 6.0 (i.e., if not completed prior to Phase 6.1
or 6.2)
- Ongoing involvement in vaccine development,testing and production
initiatives
|
F (Lead: PHAC HPFB, manufacturers) |
Preparation/Implement ation of mass immunization clinics |
- Review and if necessary revise recommended priority groups
for immunization based on available epidemiological data
|
F, P/T (Lead: PIC) |
- Modify or refine nationally defined priority target groups
depending on local circumstances
|
P/T, L |
- Modify or refine other aspect of the federal guidelines, as
needed for P/T and local application
|
P/T, L |
- Review and modify if necessary, plans for vaccine security
(i.e., during, transport, storage and clinic administration)
|
P/T, L |
- As per Phase 6.0, when vaccine is available
|
|
- National coordination on vaccine purchase
|
F,P/T (Lead: PHAC) |
- Activate immunization clinic capability
|
P/T,L |
- Implement streamlined AEFI surveillance, in collaboration
with PHAC
|
F, P/T, L (Lead: PHAC) |
- Arrange for direct shipping of vaccine to health districts
|
F (Lead: PWGSC) |
- Communicate with bordering jurisdictions (other P/Ts and the
U.S.) to facilitate awareness of the vaccine distribution plan
and coordination and collaboration on efforts as much as possible
|
F, P/T, L |
Antivirals |
Strategic and controlled use of antivirals |
- If not previously completed in Phase 6.0, review and if necessary
revise national recommendations on antiviral use based on available
epidemiological data
|
F, P/T (Lead: PIC) |
- Based on local epidemiology and available supplies, administer
antiviral treatment and prophylaxis according to national priority
groups
|
F, P/T, L |
- Communicate with bordering jurisdictions to facilitate awareness
of any antiviral distribution plans
|
F, P/T, L |
- If antivirals are being used, ensure that stakeholders are aware
of how to report adverse drug reactions
|
F, P/T (Lead: HPFB) |
- Monitor for drug resistance
|
F, P/T, L (Lead: NML) |
Health Services |
Management of increased demand on health care system |
Mostly Phase 6.2 actions: |
|
- Implement protocols and guidelines for prioritization of laboratory
services during times of high service demand and staff and supply
shortages
|
P/T, L |
- Implement mechanisms for coordinating patient transport and
tracking/managing beds e.g. central bed registries, call centre
and centralized ambulance dispatch
|
P/T, L |
- Access sources of additional HCWs and volunteers i.e., Emergency
Measures Organizations and NGOs (Red Cross, St. John ambulance)
|
F, P/T, L (Lead: PHAC) |
- Acquire extra supplies needed to provide medical care in non-traditional
sites and open non-traditional sites as needed
|
P/T, L |
- Coordinate clinical care and health services activities with
bordering jurisdictions to avoid migration to centres of perceived
enhanced services
|
P/T, L |
- Monitor capacity of mortuary and burial services as well as
need for social and psychological services for families of victims;
Implement and establish alternative sites for provision of services
as necessary
|
P/T, L |
- Track national stocks of medications as well as necessary medical
equipment and supplies, including ventilators, oxygen, etc. Consider
strategies to mitigate shortfalls
When incidence appears to be decreasing (i.e., end of a pandemic
wave) |
P/T, L |
- Assess status of stocks, impact of first wave, reorder supplies
and ensure circulation of staff to avoid burnout, across all health
care services (including mortuary)
|
P/T, L |
Public Health Measures |
Implementation of public health response |
- Case and contact management as per Annex M (Public Health Measures)
for Phase 6.1 and 6.2
|
F, P/T, L |
- Discontinue quarantine strategy if previously implemented
|
F, P/T, L |
- Shift-focus to self-care and self-monitoring as case numbers
increase, with concurrent increase in public education messaging
|
F, P/T, L |
- Implement national recommendations regarding control strategies
(i.e., cancellation of public gatherings, school closures)
|
P/T, L |
Communications |
|
|
|
Emergency Management and Coordination |
- For Phase 6.1 as per Phase 6.0 and;
|
|
- Consider declaring Public Welfare Emergency (as per Emergencies
Act)
|
F |
- Track National stocks. Consider strategies to mitigate shortfalls
|
F (Lead : PHAC) |
- Discontinue border strategies
|
F (Lead : PHAC) |
- Conduct prediction analysis
|
F (Lead : PHAC) |
- Define clinical spectrum of disease
|
F |
- Review mass facilities plan
|
F,P/T,L |
- Review distribution policy of resources allocation
|
F (Lead : PHAC) |
- Assign medical and other resources
|
F,P/T,L |
- Access sources of additional HCW`s and volunteers
|
F,P/T,L |
- For Phase 6.2 as per Phase 6.1 and;
|
|
|
F,P/T,L |
- Advise and assist P/T's on establishment and operations of non-traditional
health care sites and clinics
|
F (Lead : PHAC) |
- Deploy HERT strategically for maximum benefit
|
F (Lead : PHAC) |
- Continue consultation with health sector partners
|
F,P/T,L |
- Planning for illness in the response team
|
F,P/T,L |
- Plan for emergency financial resources
|
F,P/T,L |
- Promote optimal use of emergency resources
|
F,P/T,L |
- Assess increased demand on health care system
|
F,P/T,L |
6.4 Post-Pandemic Period
The following actions that pertain to the Post-Pandemic Period have been
retained in this section of the Plan pending completion of the Recovery
Section (anticipated for next edition of the Plan).
Component |
Focus |
Actions |
Response Level |
Surveillance |
Review, evaluation and return to routine operations |
- Resume routine ongoing laboratory and disease surveillance
|
F, P/T, L |
- Estimate burden of disease during outbreak periods
|
F, P/T |
- Evaluate surveillance during the pandemic and make recommendations
for improvements
|
F, P/T |
Vaccine Programs |
Review, evaluation, resumption of routine programs |
- Provide recommendations for routine prevention and control including
recommendations for vaccines
If vaccine was available and administered in earlier phase(s) |
F, P/T (Lead: PIC / NACI) |
- Expand vaccine programs to cover population not yet immunized
|
P/T, L |
- Summarize and report coverage data (with one and/or two doses)
and AEFI data
|
F, P/T, L |
|
F, P/T (Lead: PIC / NACI) |
- Review and if necessary revise guidelines and/or protocols used
during the mass campaigns
|
P/T, L |
Antivirals |
Review and evaluation |
- Perform inventory assessment and ongoing monitoring of antiviral
availability
|
F, P/T (Lead: PHAC) |
- Evaluate effectiveness of strategic antiviral use (in Canada
and/or based on international reports)
|
F, P/T (Lead: PIC) |
- Summarize and report antiviral resistance data
|
F (Lead: NML) |
- Summarize and report adverse drug reaction data
|
F (Lead: HPFB) |
- Provide recommendations for the strategic use of antivirals
during a pandemic based on lessons learned within Canada and internationally
|
F, P/T (Lead: PIC) |
Health Services |
Review, evaluation, return to routine operations |
- Review and activate aftercare and recovery plans and guidelines
|
P/T, L |
- Review and revise (if necessary) clinical management guidelines
|
F, P/T (Lead: PIC) |
- Review and revise (if necessary) infection control guidelines
|
F, P/T (Lead: PIC) |
- Review and revise (if necessary) guidelines for management of
mass fatalities (if applicable)
|
F, P/T (Lead: PIC) |
- Close or reduce use of "alternate care" and "over-flow
sites"
|
P/T, L |
- Restock laboratory supplies and resume routine laboratory services
|
F, P/T, L |
- Develop projections for future laboratory requirements (i.e.,
human and physical resources including test kits, etc.)
|
F, P/T |
- Summarize, evaluate and report on the use of social and psychological
services for families of victims
|
P/T, L |
- Track national stocks of medications as well as necessary medical
equipment and supplies, including ventilators, oxygen, etc. Consider
strategies to mitigate shortfalls in next wave or pandemic
|
F, P/T, L |
Public Health Measures |
Review, evaluation, resumption of routine programs |
- Review and revise (if necessary) public health management guidelines
|
F, P/T (Lead: PIC) |
- Document and report lessons learned
|
F, P/T, L |
- Update educational materials
|
F, P/T, L |
- Resume routine public health activities and programs
|
F, P/T, L |
- Promote immunization for influenza and other secondary infections
observed during the pandemic (if appropriate and applicable)
|
P/T, L |
- Disseminate all revised guidelines to appropriate stakeholders
|
F, P/T, L |
- Evaluate the effectiveness of public health measures (e.g.,
closure of schools or other institutions etc.)
|
F, P/T, L |
- Provide recommendations for routine prevention and control including
recommendations for any control measures other than vaccines and
antivirals
|
F, P/T (Lead: PIC) |
- Provide lessons learned for ourselves and the public and prepare
for the next emerging infectious disease
|
F, P/T, L |
Communications |
|
|
|
Emergency Management and Coordination |
|
F, P/T, L |
|
F, P/T, L |
|
F, P/T, L |
- Restock supplies and equipment
|
F, P/T, L |
- Implement recovery measures as required
|
F, P/T, L |
- Update educational materials
|
F, P/T, L |
[Previous] [Table of Contents] [Next]
|